The Company has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg & 20mg, which are therapeutically equivalent to Feldene Capsules 10mg & 20mg of Pfizer, Inc. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA). For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg given orally once daily. If desired, the daily dose may be divided. Usually lowest effective dosage for the shortest duration, consistent with individual patient treatment goals is recommended. The product will be commercialized from Unichem’s Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.

Q4 FY-17

March 31, 2017

Newspaper Advertisement of Audited Financial results for Q4 & Year End FY 2017
Notice of Board Meeting – Newspaper Advertisement.
Notice of Board Meeting
Corporate Governance Report as on March 31, 2017
Reconciliation of Share Capital as on March 31, 2017
Certificate under regulation 40(9) & 40 (10) as on March 31, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3) as on March 31, 2017
Compliance Certificate – Regulation 7(3) as on March 31, 2017

March 20, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s Formulation manufacturing facility at Goa was inspected by USFDA from March 14th 2017 to March 20th 2017. There were few observations made, and these in the opinion of the Company are correctable ones in respect to which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

March 8, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

March 6, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

Q3 FY-17

December 31, 2016

Reconciliation of Share Capital as on December 31, 2016
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter December 31, 2016
Notice of Board Meeting – Newspaper Advertisement
Newspaper Advertisement of Unaudited Standalone Financial results (Business Standard)
Notice of Board Meeting
Corporate Governance Report as on December 31, 2016